EPRX.US Eupraxia Pharmaceuticals Inc. Common Stock

Healthcare Biotechnology USA Stocks
8.15 USD
Close of Nov 14, 2026
5.63 9.32
Market cap
USD 548M
P/E
-
P/B
5.17x
ROE
-46.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EPRX.US undervalued?

Graham number

The Graham number of Eupraxia Pharmaceuticals Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eupraxia Pharmaceuticals Inc. Common Stock fundamental analysis

No fundamental analysis for Eupraxia Pharmaceuticals Inc. Common Stock yet.

Eupraxia Pharmaceuticals Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eupraxia Pharmaceuticals Inc. Common Stock

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophil…

Full company profile